Lysine Demethylase Inhibitor (17-AAG) Effect on Breast Cancer Cells (MCF7)

Abstract

Histone lysine demethylases (KDM4) subfamily genes that are also considered as protooncogenes have a role in switching the genes on and off in normal as well as cancer tissues. Breast cancer driver genes are induced after the overexpression of KDM4s due to removal of the repressive histone mark H3K9me3, with the concomitant activation of the estrogen receptor pathway leading to the formation of tumors in the breast tissue. The emergence of KDM4 inhibitors made it possible to use them to inhibit cancer growth. One example is Geldanamycin and its derivative 17-AAG (17-(Allylamino)-17- demethoxygeldanamycin) which are also Hsp90 inhibitors. We investigated this inhibitor in breast cancer cell lines (MCF7) and qualitatively analyzed its cellular toxicity.